XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.3
Statement of Changes in Stockholders' Equity - USD ($)
Series A Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at Jun. 30, 2024 $ 9 $ 131 $ 150,838,832 $ (139,374,895) $ 11,464,077
Balance (in shares) at Jun. 30, 2024 892,625 13,144,055      
Proceeds from sale of common stock in connection with equity financings net of issuance costs   $ 9 1,710,129   1,710,138
Proceeds from sale of common stock in connection with equity financings net of issuance costs (in shares)   893,006      
Series A preferred stock issued for employee stock compensation     14,408   14,408
Series A preferred stock issued for employee stock compensation (in shares) 10,591        
Common stock issued for consulting and legal services rendered     34,500   34,500
Common stock issued for consulting and legal services rendered (in shares)   19,713      
Warrants issued to Scientific Advisory Board     229   229
Common shares issued for Directors fees     11,250   11,250
Common shares issued for Directors fees (in shares)   6,039      
Net loss $ 0 $ 0 0 (3,126,811) (3,126,811)
Balance at Sep. 30, 2024 $ 9 $ 140 152,609,348 (142,501,706) 10,107,791
Balance (in shares) at Sep. 30, 2024 903,216 14,062,813      
Balance at Jun. 30, 2025 $ 9 $ 166 156,359,252 (148,841,861) 7,517,566
Balance (in shares) at Jun. 30, 2025 905,717 16,606,832      
Proceeds from sale of common stock in connection with equity financings net of issuance costs   $ 9 1,245,310   1,245,319
Proceeds from sale of common stock in connection with equity financings net of issuance costs (in shares)   824,535      
Series A preferred stock issued for employee stock compensation     11,632   11,632
Series A preferred stock issued for employee stock compensation (in shares) 10,591        
Common stock issued for consulting and legal services rendered   $ 1 173,849   173,850
Common stock issued for consulting and legal services rendered (in shares)   117,208      
Warrants issued to Scientific Advisory Board $ 0 $ 0 135 0 135
Common shares issued for Directors fees     11,250   11,250
Common shares issued for Directors fees (in shares)   7,504      
Net loss       (1,785,058) (1,785,058)
Balance at Sep. 30, 2025 $ 9 $ 176 $ 157,801,428 $ (150,626,919) $ 7,174,694
Balance (in shares) at Sep. 30, 2025 916,308 17,556,079